EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion

Jiwei Cheng, Haibo Ma, Xin Qian, Wenqun Xing

Cellular Oncology · 2026

DOI: 10.1007/s13402-026-01204-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2026. Verfasst von Jiwei Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoadjuvant Therapy, Chemokine CCL2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: a key project jointly built by the provincial and ministerial authorities of the Health Commission of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsNeoadjuvant TherapyChemokine CCL2Drug Resistance, NeoplasmImmune EvasionHumansAnimalsCell Line, TumorTumor MicroenvironmentSignal TransductionMaleMiceFemaleGene Expression Regulation, NeoplasticMethylationRNA Methylation

Stichwörter der Autor:innen

ADAMDEC1ChemoresistanceEoadjuvant therapyEsophageal squamous cell carcinoma (ESCA)O-GlcNAcylation

Substanzen

Chemokine CCL2

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450008, China.
  • Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127, Dongming Road, Zhengzhou, 450008, China. xingwenqun1967@163.com.

Förderung

  • a key project jointly built by the provincial and ministerial authorities of the Health Commission of Henan Province

Zitieren

APA

Cheng, J., Ma, H., Qian, X., & Xing, W. (2026). ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion. Cellular Oncology. https://doi.org/10.1007/s13402-026-01204-7

Vancouver

Cheng J, Ma H, Qian X, Xing W. ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion. Cellular Oncology. 2026. doi:10.1007/s13402-026-01204-7

BibTeX
@article{Cheng2026,
  author = {Cheng, Jiwei and Ma, Haibo and Qian, Xin and Xing, Wenqun},
  title = {ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-026-01204-7}
}
Kostenlos starten →